Merck’s ophthalmology candidate, remigromig, met the primary endpoint in a pivotal study, but the full results raise questions about the drug’s commercial prospects.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.